Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-05-18
2010-02-02
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S239100, C424S247100
Reexamination Certificate
active
07655243
ABSTRACT:
Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.
REFERENCES:
patent: 1695107 (1928-12-01), Kahl
patent: 4767402 (1988-08-01), Kost et al.
patent: 5286254 (1994-02-01), Shapland et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5964223 (1999-10-01), Baran
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6361554 (2002-03-01), Brisken
patent: 6447785 (2002-09-01), Donovan
patent: 6448231 (2002-09-01), Graham
patent: 6464680 (2002-10-01), Brisken et al.
patent: 6526976 (2003-03-01), Baran
patent: 6601581 (2003-08-01), Babaev
patent: 6620415 (2003-09-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6626855 (2003-09-01), Weng et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6645496 (2003-11-01), Aoki et al.
patent: 6649161 (2003-11-01), Donovan
patent: 6719694 (2004-04-01), Weng et al.
patent: 6740321 (2004-05-01), Donovan
patent: 6767544 (2004-07-01), Brooks et al.
patent: 6773711 (2004-08-01), Voet et al.
patent: 6776991 (2004-08-01), Naumann
patent: 6827931 (2004-12-01), Donovan
patent: 6838434 (2005-01-01), Voet
patent: 6841156 (2005-01-01), Aoki et al.
patent: 6843998 (2005-01-01), Steward et al.
patent: 6847849 (2005-01-01), Mamo et al.
patent: 6861058 (2005-03-01), Aoki et al.
patent: 6872397 (2005-03-01), Aoki et al.
patent: 6974578 (2005-12-01), Aoki et al.
patent: 2001/0044596 (2001-11-01), Jaafar
patent: 2002/0198512 (2002-12-01), Seward
patent: 2003/0050591 (2003-03-01), Patrick McHale
patent: 2003/0202990 (2003-10-01), Donovan et al.
patent: 2003/0211121 (2003-11-01), Donovan
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0010290 (2004-01-01), Schroeppel et al.
patent: 2004/0086531 (2004-05-01), Barron
patent: 2004/0091880 (2004-05-01), Wiebusch et al.
patent: 2004/0142005 (2004-07-01), Brooks et al.
patent: 2004/0151741 (2004-08-01), Borodic
patent: 2004/0175399 (2004-09-01), Schiffman
patent: 2004/0213813 (2004-10-01), Ackerman
patent: 2004/0213814 (2004-10-01), Ackerman
patent: 2004/0226556 (2004-11-01), Deem et al.
patent: 2004/0253274 (2004-12-01), Voet
patent: 2005/0019346 (2005-01-01), Boulis
patent: 2005/0074461 (2005-04-01), Donovan
patent: 2005/0107853 (2005-05-01), Krespi et al.
patent: 2005/0152924 (2005-07-01), Voet
patent: 2006/0106361 (2006-05-01), Muni et al.
patent: 2007/0021803 (2007-01-01), Deem et al.
patent: WO 2004/101028 (2004-11-01), None
International Search Report and Written Opinion of PCT/US07/69391, dated Mar. 3, 2008, 7 pages total.
Ahnert-Hilger et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromacytoma Cells (PC12) by Permeabilization with Streptolysin-Oinhibitory Effect of Tetanus Toxin on Catecholamine Secretion,”J. Neurochem. Jun. 1989; 52(6):1751-1758.
Bigalke et al., “Clostridial Toxins”,Handbook of Experimental Pharmacology(Aktories, K., and Just, I., eds) 2000, 145:407-443, Springer Verlag, Berlin, Heidelberg.
Bittner et al., “Isolated Light Chains of Botulinum Neurotoxins Inhibit Exocytosis. Studies in Digitonin-Permeabilized Chromaffin Cells.”J Biol ChemJun. 25, 1989; 264(18):10354-10360.
Buzzi, “Diphteria Toxin Treatment of Human Advanced Cancer,” Cancer Research, 1982, 42:2054-2058.
Chaddock et al “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium Botulinum Toxin Type A,”Protein Expression and Purification, Jul. 2002, 25( 2): 219-228.
Chang, “Cell Poration and Cell Fusion Using an Oscillating Electric Field,”Biophys J. Oct. 1989; 56(4): 641-652.
Guzman et al., “Bioeffects Caused by Changes in Acuostic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,”Ultrasound in Med.&Biol., 2003, 29(8): 1211-1222.
Kistner et al, “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain. Evidence for Two Redox Isomers of Tetanus Toxin,”Naunyn Schmiedebergs Arch Pharmacol. Feb. 1992; 345(2):227-34.
Kreitman, “Taming Ricin,”Nature Biotechnology, 2003, 21:372-374.
Shaari et al., “Rhinorrhea is Decreased in Dogs After Nasal Application of Botulinum Toxin,”Otolaryngol Head Neck Surg1995;112:566-571.
Simpson et al., “Isolation and Characterization of the Botulinum Neurotoxins,”Methods Enzymol. 1988; 165:76-85.
Unal et al, “Effect of Botulinum Toxin Type A on Nasal Symptons in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial,”Acta Oto-Laryngologica,, Dec. 2003, 123(9):1060-0163.
Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,”Cell Biochem. Apr. 1993; 51(4):426-35.
De Paiva et al., “Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes,”FEBS Lett. Dec. 17, 1990;277(1-2):171-174.
Raj, Editorial,Pain Practice, 2004; 4(1S): S1-S3.
Sundaram et al., “An Experimental and Theoretical Analysis of Ultrasound-Induced Permeabilization of Cell Membranes,”Biophysical Journal, May 1, 2003; 84( 5): 3087-3101.
Deem Mark E.
Gifford Hanson
Grainger, Esq. Jeffry
Navarro Mark
The Foundry, LLC
Townsend and Townsend / and Crew LLP
LandOfFree
Methods and systems for toxin delivery to the nasal cavity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and systems for toxin delivery to the nasal cavity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and systems for toxin delivery to the nasal cavity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4188536